Cox-2 Inhibitors

Our law firm, has been in the forefront of the effort to have all of the cyclooxygenase-2 (COX-2) inhibitors (Bextra, Celebrex, and Vioxx) taken off the market since the law firm took on its first case against Merck over 6 years ago.

Beasley Allen is spearheading the review of over 31,000 claims against the manufacturers of Bextra, Celebrex, and Vioxx.

One of the most popular in the COX-2 class, Vioxx - used by tens of millions of people worldwide was pulled off the market September 30, 2004. This decision came shortly after a medical conference where FDA researcher David Graham showed higher doses of Vioxx correlated with a tripled risk of heart attack or sudden cardiac death compared to people who weren't taking any similar drug.

Pfizer (the manufacturer of Celebrex and Bextra) suspended sales of their arthritis drug, Bextra, following a recommendation from the FDA. Despite numerous published studies which undeniably link the COX-2 inhibitors to a greater risk of heart-attacks, strokes and even Stevens Johnson Syndrome (SJS), as well as a stern warning from the FDA in December of 2004, Pfizer was unwilling to voluntarily pull its drugs off the market until April 7, 2005.

Following the recall of Bextra, Pfizer continues to manufacture the only remaining COX-2 inhibitor, Celebrex.